VEGFA Status as a Predictive Marker of Therapy Outcome in Metastatic Gastric Cancer Patients Following Ramucirumab-Based Treatment

VEGFA Status as a Predictive Marker of Therapy Outcome in Metastatic Gastric Cancer Patients Following Ramucirumab-Based Treatment

Metastatic gastric cancer (mGC) often has a poor prognosis and may benefit from a few targeted therapies. Ramucirumab-based anti-angiogenic therapy targeting the VEGFR2 represents a milestone in the second-line treatment of mGC. Several studies on different cancers are focusing on the major VEGFR2 l...

Full description

Bibliographic Details
Main Authors: Annalisa Schirizzi, Aram Arshadi, Doron Tolomeo, Laura Schirosi, Anna Maria Valentini, Giampiero De Leonardis, Maria Grazia Refolo, Rossella Donghia, Clelia Tiziana Storlazzi, Alfredo Zito, Angela Dalia Ricci, Simona Vallarelli, Carmela Ostuni, Maria Bencivenga, Giovanni De Manzoni, Caterina Messa, Raffaele Armentano, Gianluigi Giannelli, Claudio Lotesoriere, Rosalba D’Alessandro
Format: Article
Language:English
Published: MDPI AG 2023-10-01
Series:Biomedicines
Subjects:
metastatic Gastric Cancer
VEGFA
anti-angiogenic therapy
predictive marker
micro-vessels
Online Access:https://www.mdpi.com/2227-9059/11/10/2721

Internet

https://www.mdpi.com/2227-9059/11/10/2721

Similar Items